The U.K. Court of Appeal has given its ruling taking the stand that the Edwards Lifesciences Corp (NYSE:EW) Sapien 3™ device had infringed on the Boston Scientific patent EP (UK) 2 926 766.The ruling was a shocker to the many that had expected it to rule otherwise and it was even more frustrating to them when it added that all claims that had been leveled against it were all valid. In other words, the Edwards Lifesciences’ appeal has been dismissed with immediate effect as was announced by Boston Scientific Corporation.
The senior vice president of Boston Scientific Desiree Ralls-Morrison in giving his speech said that they were pleased the ruling had been made in their favor. According to him, the landmark ruling by the U.K. court was crucial because it validated their patents, something they had been looking forward to over quite a long period of time.
It is a new dawn for those patients that have over the years struggled with severe and symptomatic aortic valve stenosis since the ruling has motivated the company to move ahead and deliver differentiated solutions to them.
Currently, this company has been conducting its business operations in the major European markets where it has been selling ACURATE neo™ Aortic Valve System. Boston Scientific is one of the companies that remain committed to enhancing lives and achieving its set business goals.
An official working with the company after attending a business conference recently was interviewed by several journalists who wanted to get his perspective about the most recent developments of the company. He outlined that as a company they were quite pleased about the fact that they had managed to clock 35 years in the industry.
According to him, the company was keen on leveraging on the latest technological advancements sweeping across the globe towards the manufacture as well as the provision of a wide range of top performance solutions, all geared towards cutting down the costs of healthcare as well as handling the unmet medical needs.